Tubulin inhibitor-based antibody-drug conjugates for cancer therapy

Molecules

Volumn 22, Issue 8, 2017, Pages

  Chen, Hao ^a   Lin, Zongtao ^a   Arnst, Kinsie E ^a   Miller, Duane D ^a   Li, Wei ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Antibody drug conjugates; Cytotoxic payloads; Linker; Monoclonal antibody; Site specific conjugation; Tubulin inhibitors

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TUBULIN MODULATOR;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG RELEASE; HUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG LIBERATION; HUMANS; IMMUNOCONJUGATES; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN MODULATORS;

EID: 85027968777     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules22081281     Document Type: Review

References (150)

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 2016, 66, 7–30. [CrossRef] [PubMed]
2. DeVita, V.T., Jr.; Chu, E. A history of cancer chemotherapy. Cancer Res. 2008, 68, 8643–8653. [CrossRef] [PubMed]
3. Chari, R.V. Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc. Chem. Res. 2008, 41, 98–107. [CrossRef] [PubMed]
4. Nishida, T.; Shirao, K.; Sawaki, A.; Koseki, M.; Okamura, T.; Ohtsu, A.; Sugiyama, T.; Miyakawa, K.; Hirota, S. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: A phase II study (STI571B1202). Int. J. Clin. Oncol. 2008, 13, 244–251. [CrossRef] [PubMed]
5. Katzel, J.A.; Fanucchi, M.P.; Li, Z. Recent advances of novel targeted therapy in non-small cell lung cancer. J. Hematol. Oncol. 2009, 2, 2. [CrossRef] [PubMed]
6. Jordan, V.C. Tamoxifen: Catalyst for the change to targeted therapy. Eur. J. Cancer 2008, 44, 30–38. [CrossRef] [PubMed]
7. Drebin, J.A.; Link, V.C.; Weinberg, R.A.; Greene, M.I. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc. Natl. Acad. Sci. USA 1986, 83, 9129–9133. [CrossRef] [PubMed]
8. Oldham, R.K.; Dillman, R.O. Monoclonal antibodies in cancer therapy: 25 years of progress. J. Clin. Oncol. 2008, 26, 1774–1777. [CrossRef] [PubMed]
9. Scott, A.M.; Wolchok, J.D.; Old, L.J. Antibody therapy of cancer. Nat. Rev. Cancer 2012, 12, 278–287. [CrossRef] [PubMed]
10. Perez, H.L.; Cardarelli, P.M.; Deshpande, S.; Gangwar, S.; Schroeder, G.M.; Vite, G.D.; Borzilleri, R.M. Antibody-drug conjugates: Current status and future directions. Drug Discov. Today 2014, 19, 869–881. [CrossRef] [PubMed]
11. Singh, S.K.; Luisi, D.L.; Pak, R.H. Antibody-drug conjugates: Design, formulation and physicochemical stability. Pharm. Res. 2015, 32, 3541–3571. [CrossRef] [PubMed]
12. Trail, P.A.; Willner, D.; Lasch, S.J.; Henderson, A.J.; Hofstead, S.; Casazza, A.M.; Firestone, R.A.; Hellstrom, I.; Hellstrom, K.E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993, 261, 212–215. [CrossRef] [PubMed]
13. Elias, D.J.; Hirschowitz, L.; Kline, L.E.; Kroener, J.F.; Dillman, R.O.; Walker, L.E.; Robb, J.A.; Timms, R.M. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma. Cancer Res. 1990, 50, 4154–4159. [PubMed]
14. Saleh, M.N.; Sugarman, S.; Murray, J.; Ostroff, J.B.; Healey, D.; Jones, D.; Daniel, C.R.; LeBherz, D.; Brewer, H.; Onetto, N.; et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J. Clin. Oncol. 2000, 18, 2282–2292. [CrossRef] [PubMed]
15. Wang, J.; Shen, W.-C.; Zaro, J.L. Antibody-Drug Conjugates: The 21st Century Magic Bullets for Cancer; Springer: New York, NY, USA, 2015; Volume 17.
16. Chari, R.V. Expanding the reach of antibody-drug conjugates. ACS Med. Chem. Lett. 2016, 7, 974–976. [CrossRef] [PubMed]
17. Senter, P.D.; Sievers, E.L. The discovery and development of brentuximab vedotin for use in relapsed hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 2012, 30, 631–637. [CrossRef] [PubMed]
18. Peters, C.; Brown, S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci. Rep. 2015, 35, e00225. [CrossRef] [PubMed]
19. Panowski, S.; Bhakta, S.; Raab, H.; Polakis, P.; Junutula, J.R. Site-specific antibody drug conjugates for cancer therapy. mAbs 2014, 6, 34–45. [CrossRef] [PubMed]
20. Chaplin, D.D. Overview of the immune response. J. Allergy Clin. Immunol. 2010, 125, S3–S23. [CrossRef] [PubMed]
21. Guo, Q.M. DNA microarray and cancer. Curr. Opin. Oncol. 2003, 15, 36–43. [CrossRef] [PubMed]
22. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344, 783–792. [CrossRef] [PubMed]
23. Larson, R.A.; Sievers, E.L.; Stadtmauer, E.A.; Lowenberg, B.; Estey, E.H.; Dombret, H.; Theobald, M.; Voliotis, D.; Bennett, J.M.; Richie, M.; et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005, 104, 1442–1452. [CrossRef] [PubMed]
24. Thurber, G.M.; Schmidt, M.M.; Wittrup, K.D. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Deliv. Rev. 2008, 60, 1421–1434. [CrossRef] [PubMed]
25. Woof, J.M.; Burton, D.R. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat. Rev. Immunol. 2004, 4, 89–99. [CrossRef] [PubMed]
26. Teicher, B.A. Antibody-drug conjugate targets. Curr. Cancer Drug Targets 2009, 9, 982–1004. [CrossRef] [PubMed]
27. Mathur, R.; Weiner, G.J. Picking the optimal target for antibody-drug conjugates. Am. Soc. Clin. Oncol. Educ. Book 2013. [CrossRef] [PubMed]
28. Mack, F.; Ritchie, M.; Sapra, P. The next generation of antibody drug conjugates. Semin. Oncol. 2014, 41, 637–652. [CrossRef] [PubMed]
29. Ritchie, M.; Tchistiakova, L.; Scott, N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. mAbs 2013, 5, 13–21. [CrossRef] [PubMed]
30. Schmidt, M.M.; Wittrup, K.D. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol. Cancer Ther. 2009, 8, 2861–2871. [CrossRef] [PubMed]
31. Holliger, P.; Hudson, P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 2005, 23, 1126–1136. [CrossRef] [PubMed]
32. Rudnick, S.I.; Lou, J.; Shaller, C.C.; Tang, Y.; Klein-Szanto, A.J.; Weiner, L.M.; Marks, J.D.; Adams, G.P. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 2011, 71, 2250–2259. [CrossRef] [PubMed]
33. Chudasama, V.; Maruani, A.; Caddick, S. Recent advances in the construction of antibody-drug conjugates. Nat. Chem. 2016, 8, 114–119. [CrossRef] [PubMed]
34. Schumacher, D.; Hackenberger, C.P.; Leonhardt, H.; Helma, J. Current Status: Site-Specific Antibody Drug Conjugates. J. Clin. Immunol. 2016, 36, 100–107. [CrossRef] [PubMed]
35. Badescu, G.; Bryant, P.; Bird, M.; Henseleit, K.; Swierkosz, J.; Parekh, V.; Tommasi, R.; Pawlisz, E.; Jurlewicz, K.; Farys, M.; et al. Bridging disulfides for stable and defined antibody drug conjugates. Bioconjug. Chem. 2014, 25, 1124–1136. [CrossRef] [PubMed]
36. Jones, M.W.; Strickland, R.A.; Schumacher, F.F.; Caddick, S.; Baker, J.R.; Gibson, M.I.; Haddleton, D.M. Polymeric dibromomaleimides as extremely efficient disulfide bridging bioconjugation and pegylation agents. J. Am. Chem. Soc. 2012, 134, 1847–1852. [CrossRef] [PubMed]
37. Maruani, A.; Smith, M.E.; Miranda, E.; Chester, K.A.; Chudasama, V.; Caddick, S. A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. Nat. Commun. 2015, 6, 6645. [CrossRef] [PubMed]
38. Junutula, J.R.; Raab, H.; Clark, S.; Bhakta, S.; Leipold, D.D.; Weir, S.; Chen, Y.; Simpson, M.; Tsai, S.P.; Dennis, M.S.; et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 2008, 26, 925–932. [CrossRef] [PubMed]
39. Axup, J.Y.; Bajjuri, K.M.; Ritland, M.; Hutchins, B.M.; Kim, C.H.; Kazane, S.A.; Halder, R.; Forsyth, J.S.; Santidrian, A.F.; Stafin, K.; et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc. Natl. Acad. Sci. USA 2012, 109, 16101–16106. [CrossRef] [PubMed]
40. Zeglis, B.M.; Davis, C.B.; Aggeler, R.; Kang, H.C.; Chen, A.; Agnew, B.J.; Lewis, J.S. Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry. Bioconjug. Chem. 2013, 24, 1057–1067. [CrossRef] [PubMed]
41. Jeger, S.; Zimmermann, K.; Blanc, A.; Grunberg, J.; Honer, M.; Hunziker, P.; Struthers, H.; Schibli, R. Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew. Chem. Int. Ed. Engl. 2010, 49, 9995–9997. [CrossRef] [PubMed]
42. Mao, H.; Hart, S.A.; Schink, A.; Pollok, B.A. Sortase-mediated protein ligation: A new method for protein engineering. J. Am. Chem. Soc. 2004, 126, 2670–2671. [CrossRef] [PubMed]
43. Qasba, P.K. Glycans of antibodies as a specific site for drug conjugation using glycosyltransferases. Bioconjug. Chem. 2015, 26, 2170–2175. [CrossRef] [PubMed]
44. Drake, P.M.; Albers, A.E.; Baker, J.; Banas, S.; Barfield, R.M.; Bhat, A.S.; de Hart, G.W.; Garofalo, A.W.; Holder, P.; Jones, L.C.; et al. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjug. Chem. 2014, 25, 1331–1341. [CrossRef] [PubMed]
45. Albers, A.E.; Garofalo, A.W.; Drake, P.M.; Kudirka, R.; de Hart, G.W.; Barfield, R.M.; Baker, J.; Banas, S.; Rabuka, D. Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates. Eur. J. Med. Chem. 2014, 88, 3–9. [CrossRef] [PubMed]
46. Schumacher, D.; Helma, J.; Mann, F.A.; Pichler, G.; Natale, F.; Krause, E.; Cardoso, M.C.; Hackenberger, C.P.; Leonhardt, H. Versatile and efficient site-specific protein functionalization by tubulin tyrosine ligase. Angew. Chem. Int. Ed. Engl. 2015, 54, 13787–13791. [CrossRef] [PubMed]
47. Janke, C. The tubulin code: Molecular components, readout mechanisms, and functions. J. Cell Biol. 2014, 206, 461–472. [CrossRef] [PubMed]
48. Prota, A.E.; Magiera, M.M.; Kuijpers, M.; Bargsten, K.; Frey, D.; Wieser, M.; Jaussi, R.; Hoogenraad, C.C.; Kammerer, R.A.; Janke, C.; et al. Structural basis of tubulin tyrosination by tubulin tyrosine ligase. J. Cell Biol. 2013, 200, 259–270. [CrossRef] [PubMed]
49. Agarwal, P.; Bertozzi, C.R. Site-specific antibody-drug conjugates: The nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug. Chem. 2015, 26, 176–192. [CrossRef] [PubMed]
50. Jain, N.; Smith, S.W.; Ghone, S.; Tomczuk, B. Current ADC linker chemistry. Pharm. Res. 2015, 32, 3526–3540. [CrossRef] [PubMed]
51. McCombs, J.R.; Owen, S.C. Antibody drug conjugates: Design and selection of linker, payload and conjugation chemistry. AAPS J. 2015, 17, 339–351. [CrossRef] [PubMed]
52. Bross, P.F.; Beitz, J.; Chen, G.; Chen, X.H.; Duffy, E.; Kieffer, L.; Roy, S.; Sridhara, R.; Rahman, A.; Williams, G.; et al. Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 2001, 7, 1490–1496. [PubMed]
53. Chari, R.V.; Miller, M.L.; Widdison, W.C. Antibody-drug conjugates: An emerging concept in cancer therapy. Angew. Chem. Int. Ed. Engl. 2014, 53, 3796–3827. [CrossRef] [PubMed]
54. Lu, J.; Jiang, F.; Lu, A.; Zhang, G. Linkers having a crucial role in antibody-drug conjugates. Int. J. Mol. Sci. 2016, 17, 561. [CrossRef] [PubMed]
55. Tsuchikama, K.; An, Z. Antibody-drug conjugates: Recent advances in conjugation and linker chemistries. Protein Cell 2016, 1–14. [CrossRef] [PubMed]
56. Nogales, E.; Wang, H.W. Structural mechanisms underlying nucleotide-dependent self-assembly of tubulin and its relatives. Curr. Opin. Struct. Biol. 2006, 16, 221–229. [CrossRef] [PubMed]
57. Akhmanova, A.; Steinmetz, M.O. Tracking the ends: A dynamic protein network controls the fate of microtubule tips. Nat. Rev. Mol. Cell Biol. 2008, 9, 309–322. [CrossRef] [PubMed]
58. Nogales, E.; Wolf, S.G.; Downing, K.H. Structure of the alpha beta tubulin dimer by electron crystallography. Nature 1998, 391, 199–203. [CrossRef] [PubMed]
59. Li, Q.; Sham, H.L.; Rosenberg, S.H. Antimitotic Agents. Annu. Rep. Med. Chem. 1999, 34, 139–148.
60. Dumontet, C.; Jordan, M.A. Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 2010, 9, 790–803. [CrossRef] [PubMed]
61. Kupchan, S.M.; Komoda, Y.; Court, W.A.; Thomas, G.J.; Smith, R.M.; Karim, A.; Gilmore, C.J.; Haltiwanger, R.C.; Bryan, R.F. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J. Am. Chem. Soc. 1972, 94, 1354–1356. [CrossRef] [PubMed]
62. Remillard, S.; Rebhun, L.I.; Howie, G.A.; Kupchan, S.M. Antimitotic activity of the potent tumor inhibitor maytansine. Science 1975, 189, 1002–1005. [CrossRef] [PubMed]
63. Issell, B.F.; Crooke, S.T. Maytansine. Cancer Treat. Rev. 1978, 5, 199–207. [CrossRef]
64. Benechie, M.; Khuong-Huu, F. Total synthesis of (−)-maytansinol. J. Org. Chem. 1996, 61, 7133–7138. [CrossRef] [PubMed]
65. Kupchan, S.M.; Sneden, A.T.; Branfman, A.R.; Howie, G.A.; Rebhun, L.I.; McIvor, W.E.; Wang, R.W.; Schnaitman, T.C. Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids. J. Med. Chem. 1978, 21, 31–37. [CrossRef] [PubMed]
66. Widdison, W.C.; Wilhelm, S.D.; Cavanagh, E.E.; Whiteman, K.R.; Leece, B.A.; Kovtun, Y.; Goldmacher, V.S.; Xie, H.; Steeves, R.M.; Lutz, R.J.; et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J. Med. Chem. 2006, 49, 4392–4408. [CrossRef] [PubMed]
67. Cassady, J.M.; Chan, K.K.; Floss, H.G.; Leistner, E. Recent developments in the maytansinoid antitumor agents. Chem. Pharm. Bull. 2004, 52, 1–26. [CrossRef] [PubMed]
68. Amiri-Kordestani, L.; Blumenthal, G.M.; Xu, Q.C.; Zhang, L.; Tang, S.W.; Ha, L.; Weinberg, W.C.; Chi, B.; Candau-Chacon, R.; Hughes, P.; et al. FDA approval: Ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin. Cancer Res. 2014, 20, 4436–4441. [CrossRef] [PubMed]
69. Erickson, H.K.; Lewis Phillips, G.D.; Leipold, D.D.; Provenzano, C.A.; Mai, E.; Johnson, H.A.; Gunter, B.; Audette, C.A.; Gupta, M.; Pinkas, J.; et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol. Cancer Ther. 2012, 11, 1133–1142. [CrossRef] [PubMed]
70. Erickson, H.K.; Park, P.U.; Widdison, W.C.; Kovtun, Y.V.; Garrett, L.M.; Hoffman, K.; Lutz, R.J.; Goldmacher, V.S.; Blattler, W.A. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006, 66, 4426–4433. [CrossRef] [PubMed]
71. Polson, A.G.; Calemine-Fenaux, J.; Chan, P.; Chang, W.; Christensen, E.; Clark, S.; de Sauvage, F.J.; Eaton, D.; Elkins, K.; Elliott, J.M.; et al. Antibody-drug conjugates for the treatment of non-Hodgkin’s lymphoma: target and linker-drug selection. Cancer Res. 2009, 69, 2358–2364. [CrossRef] [PubMed]
72. Erickson, H.K.; Widdison, W.C.; Mayo, M.F.; Audette, C.; Wilhelm, S.D. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody—Maytansinoid conjugates. Bioconjug. Chem. 2010, 21, 84–92. [CrossRef] [PubMed]
73. Lewis Phillips, G.D.; Li, G.; Dugger, D.L.; Crocker, L.M.; Parsons, K.L.; Mai, E.; Blattler, W.A.; Lambert, J.M.; Chari, R.V.; Lutz, R.J.; et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008, 68, 9280–9290. [CrossRef] [PubMed]
74. Sun, X.; Widdison, W.; Mayo, M.; Wilhelm, S.; Leece, B.; Chari, R.; Singh, R.; Erickson, H. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug. Chem. 2011, 22, 728–735. [CrossRef] [PubMed]
75. Dosio, F.; Brusa, P.; Cattel, L. Immunotoxins and anticancer drug conjugate assemblies: The role of the linkage between components. Toxins 2011, 3, 848–883. [CrossRef] [PubMed]
76. Kovtun, Y.V.; Audette, C.A.; Mayo, M.F.; Jones, G.E.; Doherty, H.; Maloney, E.K.; Erickson, H.K.; Sun, X.; Wilhelm, S.; Ab, O.; et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 2010, 70, 2528–2537. [CrossRef] [PubMed]
77. Zhao, R.Y.; Wilhelm, S.D.; Audette, C.; Jones, G.; Leece, B.A.; Lazar, A.C.; Goldmacher, V.S.; Singh, R.; Kovtun, Y.; Widdison, W.C.; et al. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J. Med. Chem. 2011, 54, 3606–3623. [CrossRef] [PubMed]
78. Bai, R.; Pettit, G.R.; Hamel, E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem. Pharmacol. 1990, 39, 1941–1949. [CrossRef]
79. Aherne, G.W.; Hardcastle, A.; Valenti, M.; Bryant, A.; Rogers, P.; Pettit, G.R.; Srirangam, J.K.; Kelland, L.R. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. Cancer Chemother. Pharmacol. 1996, 38, 225–232. [CrossRef] [PubMed]
80. Garteiz, D.A.; Madden, T.; Beck, D.E.; Huie, W.R.; McManus, K.T.; Abbruzzese, J.L.; Chen, W.; Newman, R.A. Quantitation of dolastatin-10 using HPLC/electrospray ionization mass spectrometry: Application in a phase I clinical trial. Cancer Chemother. Pharmacol. 1998, 41, 299–306. [CrossRef] [PubMed]
81. Krug, L.M.; Miller, V.A.; Kalemkerian, G.P.; Kraut, M.J.; Ng, K.K.; Heelan, R.T.; Pizzo, B.A.; Perez, W.; McClean, N.; Kris, M.G. Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. Ann. Oncol. 2000, 11, 227–228. [CrossRef] [PubMed]
82. Doronina, S.O.; Toki, B.E.; Torgov, M.Y.; Mendelsohn, B.A.; Cerveny, C.G.; Chace, D.F.; DeBlanc, R.L.; Gearing, R.P.; Bovee, T.D.; Siegall, C.B.; et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 2003, 21, 778–784. [CrossRef] [PubMed]
83. Doronina, S.O.; Mendelsohn, B.A.; Bovee, T.D.; Cerveny, C.G.; Alley, S.C.; Meyer, D.L.; Oflazoglu, E.; Toki, B.E.; Sanderson, R.J.; Zabinski, R.F.; et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. Bioconjug. Chem. 2006, 17, 114–124. [CrossRef] [PubMed]
84. Francisco, J.A.; Cerveny, C.G.; Meyer, D.L.; Mixan, B.J.; Klussman, K.; Chace, D.F.; Rejniak, S.X.; Gordon, K.A.; DeBlanc, R.; Toki, B.E.; et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003, 102, 1458–1465. [CrossRef] [PubMed]
85. Dubowchik, G.M.; Firestone, R.A.; Padilla, L.; Willner, D.; Hofstead, S.J.; Mosure, K.; Knipe, J.O.; Lasch, S.J.; Trail, P.A. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug. Chem. 2002, 13, 855–869. [CrossRef] [PubMed]
86. Doronina, S.O.; Bovee, T.D.; Meyer, D.W.; Miyamoto, J.B.; Anderson, M.E.; Morris-Tilden, C.A.; Senter, P.D. Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug. Chem. 2008, 19, 1960–1963. [CrossRef] [PubMed]
87. Younes, A.; Bartlett, N.L.; Leonard, J.P.; Kennedy, D.A.; Lynch, C.M.; Sievers, E.L.; Forero-Torres, A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 2010, 363, 1812–1821. [CrossRef] [PubMed]
88. Katz, J.; Janik, J.E.; Younes, A. Brentuximab Vedotin (SGN-35). Clin. Cancer Res. 2011, 17, 6428–6436. [CrossRef] [PubMed]
89. Chen, R.; Gopal, A.; Smith, S.; Ansell, S.; Rosenblatt, J.; Savage, K.; Connors, J.; Engert, A.; Larsen, E.; Kennedy, D. Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory hodgkin lymphoma (HL). J. Clin. Oncol. 2011, 29, 8031. [CrossRef]
90. Singh, R.; Erickson, H.K. Antibody-cytotoxic agent conjugates: Preparation and characterization. Methods Mol. Biol. 2009, 525, 445–467. [PubMed]
91. Doronina, S.; Alley, S.; Cerveney, C.; Francisco, J.; Law, C.-L.; Mendelsohn, B.; Okeley, N.; Sanderson, R.; Wahl, A.; Senter, P. Novel linkers for monoclonal antibody-mediated delivery of cell impermeable anticancer agents. Cancer Res. 2005, 65, 333.
92. Jeffrey, S.C.; Andreyka, J.B.; Bernhardt, S.X.; Kissler, K.M.; Kline, T.; Lenox, J.S.; Moser, R.F.; Nguyen, M.T.; Okeley, N.M.; Stone, I.J.; et al. Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates. Bioconjug. Chem. 2006, 17, 831–840. [CrossRef] [PubMed]
93. Burke, P.J.; Hamilton, J.Z.; Pires, T.A.; Setter, J.R.; Hunter, J.H.; Cochran, J.H.; Waight, A.B.; Gordon, K.A.; Toki, B.E.; Emmerton, K.K.; et al. Development of novel quaternary ammonium linkers for antibody-drug conjugates. Mol. Cancer Ther. 2016, 15, 938–945. [CrossRef] [PubMed]
94. Bryant, P.; Pabst, M.; Badescu, G.; Bird, M.; McDowell, W.; Jamieson, E.; Swierkosz, J.; Jurlewicz, K.; Tommasi, R.; Henseleit, K.; et al. In vitro and in vivo evaluation of cysteine rebridged trastuzumab-MMAE antibody drug conjugates with defined drug-to-antibody ratios. Mol. Pharm. 2015, 12, 1872–1879. [CrossRef] [PubMed]
95. Schwartz, R.E.; Hirsch, C.F.; Sesin, D.F.; Flor, J.E.; Chartrain, M.; Fromtling, R.E.; Harris, G.H.; Salvatore, M.J.; Liesch, J.M.; Yudin, K. Pharmaceuticals from cultured algae. J. Ind. Microbiol. 1990, 5, 113–123. [CrossRef]
96. Trimurtulu, G.; Ohtani, I.; Patterson, G.M.L.; Moore, R.E.; Corbett, T.H.; Valeriote, F.A.; Demchik, L. Total structures of cryptophycins, potent antitumor depsipeptides from the Blue-green alga nostoc sp. strain GSV 224. J. Am. Chem. Soc. 1994, 116, 4729–4737. [CrossRef]
97. Smith, C.D.; Zhang, X.; Mooberry, S.L.; Patterson, G.M.; Moore, R.E. Cryptophycin: A new antimicrotubule agent active against drug-resistant cells. Cancer Res. 1994, 54, 3779–3784. [PubMed]
98. Smith, A.B.; Cho, Y.S.; Pettit, G.R.; Hirschmann, R. Design, synthesis, and evaluation of azepine-based cryptophycin mimetics. Tetrahedron 2003, 59, 6991–7009. [CrossRef]
99. Patel, V.F.; Andis, S.L.; Kennedy, J.H.; Ray, J.E.; Schultz, R.M. Novel cryptophycin antitumor agents: Synthesis and cytotoxicity of fragment “B” analogues. J. Med. Chem. 1999, 42, 2588–2603. [CrossRef] [PubMed]
100. Eggen, M.; Georg, G.I. The cryptophycins: their synthesis and anticancer activity. Med. Res. Rev. 2002, 22, 85–101. [CrossRef] [PubMed]
101. Georg, G.I.; Ali, S.M.; Stella, V.J.; Waugh, W.N.; Himes, R.H. Halohydrin analogues of cryptophycin 1: Synthesis and biological activity. Bioorg. Med. Chem. Lett. 1998, 8, 1959–1962. [CrossRef]
102. Al-Awar, R.S.; Ray, J.E.; Schultz, R.M.; Andis, S.L.; Kennedy, J.H.; Moore, R.E.; Liang, J.; Golakoti, T.; Subbaraju, G.V.; Corbett, T.H. A convergent approach to cryptophycin 52 analogues: Synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins. J. Med. Chem. 2003, 46, 2985–3007. [CrossRef] [PubMed]
103. Weiss, C.; Sammet, B.; Sewald, N. Recent approaches for the synthesis of modified cryptophycins. Nat. Prod. Rep. 2013, 30, 924–940. [CrossRef] [PubMed]
104. Weiss, C.; Bogner, T.; Sammet, B.; Sewald, N. Total synthesis and biological evaluation of fluorinated cryptophycins. Beilstein J. Org. Chem. 2012, 8, 2060–2066. [CrossRef] [PubMed]
105. Varie, D.L.; Shih, C.; Hay, D.A.; Andis, S.L.; Corbett, T.H.; Gossett, L.S.; Janisse, S.K.; Martinelli, M.J.; Moher, E.D.; Schultz, R.M.; et al. Synthesis and biological evaluation of cryptophycin analogs with substitution at C-6 (fragment C region). Bioorg. Med. Chem. Lett. 1999, 9, 369–374. [CrossRef]
106. Nahrwold, M.; Bogner, T.; Eissler, S.; Verma, S.; Sewald, N. “Clicktophycin-52”: A bioactive cryptophycin-52 triazole analogue. Org. Lett. 2010, 12, 1064–1067. [CrossRef] [PubMed]
107. Nahrwold, M.; Weiss, C.; Bogner, T.; Mertink, F.; Conradi, J.; Sammet, B.; Palmisano, R.; Royo Gracia, S.; Preusse, T.; Sewald, N. Conjugates of modified cryptophycins and RGD-peptides enter target cells by endocytosis. J. Med. Chem. 2013, 56, 1853–1864. [CrossRef] [PubMed]
108. Buck, S.B.; Huff, J.K.; Himes, R.H.; Georg, G.I. Total synthesis and anti-tubulin activity of epi-c3 analogues of cryptophycin-24. J. Med. Chem. 2004, 47, 3697–3699. [CrossRef] [PubMed]
109. Golakoti, T.; Ogino, J.; Heltzel, C.E.; Le Husebo, T.; Jensen, C.M.; Larsen, L.K.; Patterson, G.M.L.; Moore, R.E.; Mooberry, S.L. Structure determination, conformational analysis, chemical stability studies, and antitumor evaluation of the cryptophycins. Isolation of 18 new analogs from Nostoc sp. strain GSV 224. J. Am. Chem. Soc. 1995, 117, 12030–12049. [CrossRef]
110. Sammet, B.; Bogner, T.; Nahrwold, M.; Weiss, C.; Sewald, N. Approaches for the synthesis of functionalized cryptophycins. J. Org. Chem. 2010, 75, 6953–6960. [CrossRef] [PubMed]
111. Stevenson, J.P.; Sun, W.; Gallagher, M.; Johnson, R.; Vaughn, D.; Schuchter, L.; Algazy, K.; Hahn, S.; Enas, N.; Ellis, D.; et al. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days. Clin. Cancer Res. 2002, 8, 2524–2529. [PubMed]
112. Sessa, C.; Weigang-Kohler, K.; Pagani, O.; Greim, G.; Mora, O.; De Pas, T.; Burgess, M.; Weimer, I.; Johnson, R. Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule. Eur. J. Cancer 2002, 38, 2388–2396. [CrossRef]
113. Edelman, M.J.; Gandara, D.R.; Hausner, P.; Israel, V.; Thornton, D.; DeSanto, J.; Doyle, L.A. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2003, 39, 197–199. [CrossRef]
114. D’Agostino, G.; del Campo, J.; Mellado, B.; Izquierdo, M.A.; Minarik, T.; Cirri, L.; Marini, L.; Perez-Gracia, J.L.; Scambia, G. A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer. Int. J. Gynecol. Cancer 2006, 16, 71–76. [CrossRef] [PubMed]
115. Verma, V.A.; Pillow, T.H.; DePalatis, L.; Li, G.; Phillips, G.L.; Polson, A.G.; Raab, H.E.; Spencer, S.; Zheng, B. The cryptophycins as potent payloads for antibody drug conjugates. Bioorg. Med. Chem. Lett. 2015, 25, 864–868. [CrossRef] [PubMed]
116. Sasse, F.; Steinmetz, H.; Heil, J.; Hofle, G.; Reichenbach, H. Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli. Production, isolation, physico-chemical and biological properties. J. Antibiot. 2000, 53, 879–885. [CrossRef] [PubMed]
117. Khalil, M.W.; Sasse, F.; Lunsdorf, H.; Elnakady, Y.A.; Reichenbach, H. Mechanism of action of tubulysin, an antimitotic peptide from myxobacteria. ChemBiolChem 2006, 7, 678–683. [CrossRef] [PubMed]
118. Leamon, C.; Reddy, J.; Wang, K.; Dorton, R.; Westrick, E.; Dawson, A.; Smith, T.; Vlahov, I.; Vetzel, M. Folate receptor specific anti-tumor activity of EC0305, a folate-tubulysin conjugate. Cancer Res. 2007, 67, 2261.
119. Cohen, R.; Vugts, D.J.; Visser, G.W.; Stigter-van Walsum, M.; Bolijn, M.; Spiga, M.; Lazzari, P.; Shankar, S.; Sani, M.; Zanda, M.; et al. Development of novel ADCs: Conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling. Cancer Res. 2014, 74, 5700–5710. [CrossRef] [PubMed]
120. Li, J.Y.; Perry, S.R.; Muniz-Medina, V.; Wang, X.; Wetzel, L.K.; Rebelatto, M.C.; Hinrichs, M.J.; Bezabeh, B.Z.; Fleming, R.L.; Dimasi, N.; et al. A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell 2016, 29, 117–129. [CrossRef] [PubMed]
121. Schluep, T.; Gunawan, P.; Ma, L.; Jensen, G.S.; Duringer, J.; Hinton, S.; Richter, W.; Hwang, J. Polymeric tubulysin-peptide nanoparticles with potent antitumor activity. Clin. Cancer Res. 2009, 15, 181–189. [CrossRef] [PubMed]
122. Patterson, A.W.; Peltier, H.M.; Sasse, F.; Ellman, J.A. Design, synthesis, and biological properties of highly potent tubulysin D analogues. Chemistry 2007, 13, 9534–9541. [CrossRef] [PubMed]
123. Shankar, S.P.; Jagodzinska, M.; Malpezzi, L.; Lazzari, P.; Manca, I.; Greig, I.R.; Sani, M.; Zanda, M. Synthesis and structure-activity relationship studies of novel tubulysin U analogues—Effect on cytotoxicity of structural variations in the tubuvaline fragment. Org. Biomol. Chem. 2013, 11, 2273–2287. [CrossRef] [PubMed]
124. Crews, P.; Farias, J.J.; Emrich, R.; Keifer, P.A. Milnamide A, an unusual cytotoxic tripeptide from the Marine sponge auletta cf. constricta. J. Org. Chem. 1994, 59, 2932–2934. [CrossRef]
125. Loganzo, F.; Discafani, C.M.; Annable, T.; Beyer, C.; Musto, S.; Hari, M.; Tan, X.; Hardy, C.; Hernandez, R.; Baxter, M.; et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res. 2003, 63, 1838–1845. [PubMed]
126. Bai, R.; Durso, N.A.; Sackett, D.L.; Hamel, E. Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: Comparison with dolastatin 10 and cryptophycin 1. Biochemistry 1999, 38, 14302–14310. [CrossRef] [PubMed]
127. Wang, Y.; Benz, F.W.; Wu, Y.; Wang, Q.; Chen, Y.; Chen, X.; Li, H.; Zhang, Y.; Zhang, R.; Yang, J. Structural insights into the pharmacophore of vinca domain inhibitors of microtubules. Mol. Pharmacol. 2016, 89, 233–242. [CrossRef] [PubMed]
128. Lesma, G.; Sacchetti, A.; Bai, R.; Basso, G.; Bortolozzi, R.; Hamel, E.; Silvani, A.; Vaiana, N.; Viola, G. Hemiasterlin analogues incorporating an aromatic, and heterocyclic type C-terminus: Design, synthesis and biological evaluation. Mol. Divers. 2014, 18, 357–373. [CrossRef] [PubMed]
129. Krishnamurthy, G.; Cheng, W.; Lo, M.C.; Aulabaugh, A.; Razinkov, V.; Ding, W.; Loganzo, F.; Zask, A.; Ellestad, G. Biophysical characterization of the interactions of HTI-286 with tubulin heterodimer and microtubules. Biochemistry 2003, 42, 13484–13495. [CrossRef] [PubMed]
130. Loganzo, F.; Hari, M.; Annable, T.; Tan, X.; Morilla, D.B.; Musto, S.; Zask, A.; Kaplan, J.; Minnick, A.A.; May, M.K. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in α-tubulin. Mol. Cancer Ther. 2004, 3, 1319–1327. [PubMed]
131. Ratain, M.; Undevia, S.; Janisch, L.; Roman, S.; Mayer, P.; Buckwalter, M.; Foss, D.; Hamilton, B.; Fischer, J.; Bukowski, R. Phase 1 and pharmacological study of HTI-286, a novel antimicrotubule agent: Correlation of neutropenia with time above a threshold serum concentration. Proc. Am. Soc. Clin. Oncol. 2003, 22, 516.
132. Harada, M.; Tsuchiya, M.; Miyazaki, R.; Inoue, T.; Tanaka, R.; Yanagisawa, Y.; Ito, M.; Ito, Y.; Naito, K. Preclinical evaluation of NC-6201, an antibody/drug-conjugated micelle incorporating novel hemiasterlin analogue E7974. In Proceedings of the AACR 107th Annual Meeting, New Orleans, LA, USA, 16–20 April 2016.
133. Wani, M.C.; Taylor, H.L.; Wall, M.E.; Coggon, P.; McPhail, A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 1971, 93, 2325–2327. [CrossRef] [PubMed]
134. Holmes, F.A.; Walters, R.S.; Theriault, R.L.; Forman, A.D.; Newton, L.K.; Raber, M.N.; Buzdar, A.U.; Frye, D.K.; Hortobagyi, G.N. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst. 1991, 83, 1797–1805. [CrossRef] [PubMed]
135. Guillemard, V.; Saragovi, H.U. Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. Cancer Res. 2001, 61, 694–699. [PubMed]
136. Ojima, I.; Geng, X.; Wu, X.; Qu, C.; Borella, C.P.; Xie, H.; Wilhelm, S.D.; Leece, B.A.; Bartle, L.M.; Goldmacher, V.S.; et al. Tumor-specific novel taxoid-monoclonal antibody conjugates. J. Med. Chem. 2002, 45, 5620–5623. [CrossRef] [PubMed]
137. Quiles, S.; Raisch, K.P.; Sanford, L.L.; Bonner, J.A.; Safavy, A. Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy. J. Med. Chem. 2010, 53, 586–594. [CrossRef] [PubMed]
138. Ojima, I.; Kuduk, S.D.; Chakravarty, S. Recent advances in the medicinal chemistry of taxoid anticancer agents. Adv. Med. Chem. 1999, 4, 69–124.
139. Singh, R.; Sharma, M.; Joshi, P.; Rawat, D.S. Clinical status of anti-cancer agents derived from marine sources. Anticancer Agents Med. Chem. 2008, 8, 603–617. [CrossRef] [PubMed]
140. Ter Haar, E.; Kowalski, R.J.; Hamel, E.; Lin, C.M.; Longley, R.E.; Gunasekera, S.P.; Rosenkranz, H.S.; Day, B.W. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 1996, 35, 243–250. [CrossRef] [PubMed]
141. Li, J.; Risinger, A.L.; Peng, J.; Chen, Z.; Hu, L.; Mooberry, S.L. Potent taccalonolides, AF and AJ, inform significant structure-activity relationships and tubulin as the binding site of these microtubule stabilizers. J. Am. Chem. Soc. 2011, 133, 19064–19067. [CrossRef] [PubMed]
142. Risinger, A.L.; Li, J.; Bennett, M.J.; Rohena, C.C.; Peng, J.; Schriemer, D.C.; Mooberry, S.L. Taccalonolide binding to tubulin imparts microtubule stability and potent in vivo activity. Cancer Res. 2013, 73, 6780–6792. [CrossRef] [PubMed]
143. Peng, J.; Risinger, A.L.; Li, J.; Mooberry, S.L. Synthetic reactions with rare taccalonolides reveal the value of C-22,23 epoxidation for microtubule stabilizing potency. J. Med. Chem. 2014, 57, 6141–6149. [CrossRef] [PubMed]
144. Ferrandina, G.; Mariani, M.; Andreoli, M.; Shahabi, S.; Scambia, G.; Ferlini, C. Novel drugs targeting microtubules: The role of epothilones. Curr. Pharm. Des. 2012, 18, 2793–2803. [CrossRef] [PubMed]
145. Prota, A.E.; Bargsten, K.; Northcote, P.T.; Marsh, M.; Altmann, K.H.; Miller, J.H.; Diaz, J.F.; Steinmetz, M.O. Structural basis of microtubule stabilization by laulimalide and peloruside A. Angew. Chem. Int. Ed. Engl. 2014, 53, 1621–1625. [CrossRef] [PubMed]
146. Sivakumar, G. Colchicine semisynthetics: Chemotherapeutics for cancer? Curr. Med. Chem. 2013, 20, 892–898. [CrossRef] [PubMed]
147. Rajak, H.; Dewangan, P.K.; Patel, V.; Jain, D.K.; Singh, A.; Veerasamy, R.; Sharma, P.C.; Dixit, A. Design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomers. Curr. Pharm. Des. 2013, 19, 1923–1955. [CrossRef] [PubMed]
148. Shan, Y.; Zhang, J.; Liu, Z.; Wang, M.; Dong, Y. Developments of combretastatin A-4 derivatives as anticancer agents. Curr. Med. Chem. 2011, 18, 523–538. [CrossRef] [PubMed]
149. Yang, J.; Wang, Y.; Wang, T.; Jiang, J.; Botting, C.H.; Liu, H.; Chen, Q.; Yang, J.; Naismith, J.H.; Zhu, X.; Chen, L. Pironetin reacts covalently with cysteine-316 of alpha-tubulin to destabilize microtubule. Nat. Commun. 2016, 7, 12103. [CrossRef] [PubMed]
150. Zhu, G.D.; Fu, Y.X. Design of next generation antibody drug conjugates. Acta Pharm. Sin. 2013, 48, 1053–1070.